A post-authorisation safety study (PASS) to describe real-world safety and effectiveness of NUCALA (mepolizumab) in paediatric eosinophilic granulomatosis with polyangiitis (EGPA) patients in Europe (218065)

03/11/2022
30/10/2025
EU PAS number:
EUPAS49460
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Protocol_NUCALA_EGPA_PASS_Protocol_Anonymized.pdf

English (1.29 MB - PDF) View document
Study results
Study report
Other information